Award for Bilobil in Poland

The first place in the national competition "Consumer's Laurel 2007" in the category "Drugs for memory improvement" has been won by Krka's Bilobil. As in the last year, also this year Bilobil won the first place in its category.

The award was based on voting by the Polish people. Bilobil turned out to be the most popular drug for memory improvement in Poland. This year Bilobil was also appreciated by pharmacists who awarded it The Product of the Year 2007 within the products for memory improvement. So it appears that Bilobil is the most highly evaluated drug in its group by patients and specialists.

Bilobil was frequently selected by the Polish pharmacists and patients who in the last year awarded it a gold "Consumer's Laurel".

Bilobil was also twice awarded a statuette of Golden Otis.

Bilobil is a drug that contains natural Ginkgo biloba leaf substances which improve the metabolism in brain cells and the supply of oxygen to the brain. The active substances of the extract improve memory and concentration, and are beneficial for life energy. The clinical examination* which was carried out in Otolaryngology Clinic Collegium Medicum in Bydgoszcz proved that the drug improves brain functions, such as memory and the ability to concentrate. Bilobil also efficiently prevents dizziness and tingling in the ears. In 2004 the producer enriched the Bilobil brand in Poland by a new product. Bilobil forte contains a double dose of Ginkgo biloba extracts (80 mg) and is intended for the active part of the population enabling a longer and a more intensive mental effort.

About Krka
Krka is one of the top generic pharmaceutical companies in Europe. For further information, please visit www.krka.si.

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

FDA approves first treatment for rare form of skin…

The U.S. Food and Drug Administration has granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with m...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

TB Alliance sublicenses promising anti-tuberculosi…

On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug c...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]